Vasogen gets patent for VasoCare component:
This article was originally published in Clinica
Executive Summary
Vasogen (Canada) has been granted a US patent for a key component of its VasoCare delivery technology for vascular disease. Treatment is on an outpatient basis and involves the exposure ex vivo of a blood sample to three physio-chemical cell stressors - UV light, heat and oxidation - followed by intramuscular reinjection. The company's technology controls the application of the cell stressors, using a disposable blood-management unit. The patent covers an electronic circuit for controlling the generation of the oxidant and its delivery to a sample of blood.